CSL889 (Etranacogene Dezaparvovec)

About CSL

CSL Limited's mission is to deliver innovative biotherapies and vaccines to patients with serious and rare diseases, leveraging a diversified portfolio and integrated business model. The company has achieved global leadership in plasma-derived therapies and influenza vaccines, underscored by strategic acquisitions like Vifor Pharma and a $1.5 billion U.S. manufacturing expansion. Its strategy centers on deepening expertise in immunology, hematology, and nephrology, driving growth through R&D investment, operational excellence, and geographic expansion to meet rising global demand for its critical therapies.

Therapeutic Areas

Other Hemophilia B Drugs